PRIME THERAPEUTICS®

1305 Corporate Center Drive
Eagan, MN 55121

www.primetherapeutics.com

Additive Toxicity Monitoring Reminder

July 16, 2014

Dear Valued Provider,

Benefit Sponsors utilize additive toxicity monitoring at point-of-sale (POS) to promote compliance with Centers for Medicare & Medicaid Services (CMS) regulations. This Covered Person monitoring program is designed to monitor the adjudication of acetaminophen (APAP) targeted drugs and prevent the dispensing of unsafe daily doses of APAP by calculating the total APAP consumption within active prescriptions.

Action Required

Participating pharmacies are expected to review additive toxicity Drug Utilization Review (DUR) alerts with Covered Persons and/or Prescribing Providers before professional pharmacy service (PPS) codes are used to override an associated claim reject. When a target drug, in conjunction with other active prescriptions, creates a potential unsafe daily dose of APAP, the claim for the target drug will reject at POS with the following reject message:

- NCPDP Reject Code 88: "DUR Reject Error. Additive toxicity: Acetaminophen daily dose > 4 grams"
- Secondary Message: "ADDITIVE TOXICITY: APAP DAILY DOSE ON ALL ACTIVE RX'S >4GM/DAY.SUBMIT PPS CODES TO OVERRIDE.HELP DESK 18006936704"

If you have questions regarding claims processing, please contact Prime's Contact Center at 1.800.693.6704.

Sincerely,

Pharmacy Network Management
Prime Therapeutics LLC